Citadel Advisors’s Mentari Therapeutics, Inc. Common Stock MTRI Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$58.4K Buy
4,297
+1,689
+65% +$24.8K ﹤0.01% 13283
2026
Q2
$40.4K Sell
2,608
-2,089
-44% -$23.1K ﹤0.01% 13215
2026
Q1
$30.3K Buy
+4,697
New +$44.3K ﹤0.01% 12568
2024
Q4
– Sell
-283
Closed -$13.3K – 14918
2024
Q3
$13.3K Buy
283
+223
+372% +$11.4K ﹤0.01% 13067
2024
Q2
$3.21K Sell
60
-4
-6% -$229 ﹤0.01% 13614
2024
Q1
$4.48K Sell
64
-106
-62% -$7.79K ﹤0.01% 13813
2023
Q4
$14.1K Buy
+170
New +$16.5K ﹤0.01% 12892
2022
Q3
– Sell
-3
Closed -$6K – 13085
2022
Q2
$6K Buy
+3
New +$11.5K ﹤0.01% 12664
2022
Q1
– Sell
-2
Closed -$14K – 14069
2021
Q4
$14K Sell
2
-2
-50% -$15.5K ﹤0.01% 13636
2021
Q3
$31K Buy
4
+1
+33% +$11.9K ﹤0.01% 13560
2021
Q2
$49K Hold
3
– – ﹤0.01% 13345
2021
Q1
$57K Buy
+3
New +$64.3K ﹤0.01% 12838

Other funds holding MTRI

Citadel Advisors's MTRI Position: Q3 2026 in Review

Citadel Advisors increased its Mentari Therapeutics, Inc. Common Stock (MTRI) stake by 65% in Q3 2026, buying an estimated $24.8K and bringing the position to 4,297 shares worth $58.4K. The position accounts for ﹤0.01% of the portfolio, ranked #13283.

Citadel Advisors first reported a position in MTRI in Q1 2021 and has held it in 12 quarters since. 16 funds tracked by Wall St. Rank hold MTRI as of Q3 2026.

  • Citadel Advisors held 4,297 shares of Mentari Therapeutics, Inc. Common Stock worth $58.4K as of Q3 2026.
  • Citadel Advisors bought 1,689 Mentari Therapeutics, Inc. Common Stock shares in Q3 2026, an estimated $24.8K.
  • Mentari Therapeutics, Inc. Common Stock made up ﹤0.01% of Citadel Advisors's portfolio in Q3 2026, its #13283 holding.
  • Citadel Advisors first reported a position in Mentari Therapeutics, Inc. Common Stock in Q1 2021 and has held it in 12 quarters since.
  • 16 funds tracked by Wall St. Rank held Mentari Therapeutics, Inc. Common Stock as of Q3 2026.

Based on Citadel Advisors's 13F filing for Q3 2026, filed 16 Nov 2026.